Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration

被引:1
|
作者
Moore, Amanda M. [1 ,2 ]
Nooruddin, Zohra [2 ]
Reveles, Kelly R. [1 ,2 ,3 ]
Koeller, Jim M. [1 ,2 ]
Whitehead, Jennifer M. [2 ,3 ]
Franklin, Kathleen [3 ]
Datta, Paromita [2 ,3 ]
Alkadimi, Munaf [2 ,3 ]
Brannman, Lance [4 ]
Cotarla, Ion [5 ]
Frankart, Andrew J. [6 ]
Mulrooney, Tiernan [5 ]
Jones, Xavier [1 ,3 ]
Frei, Christopher R. [1 ,2 ,3 ,7 ]
机构
[1] Univ Texas Austin, Coll Pharm, Div Pharmacotherapy, San Antonio, TX USA
[2] Univ Texas Hlth San Antonio, Pharmacotherapy Educ & Res Ctr, Long Sch Med, Dept Med, San Antonio, TX USA
[3] Audie L Murphy Mem Vet Hosp Div, Res Serv, South Texas Vet Hlth Care Syst, San Antonio, TX USA
[4] Global Med Affairs, Oncol Business Unit, AstraZeneca Pharmaceut, Gaithersburg, MD USA
[5] US Med Affairs, Oncol Business Unit, AstraZeneca Pharmaceut, Gaithersburg, MD USA
[6] Univ Cincinnati, Dept Radiat Oncol, Cincinnati, OH USA
[7] Univ Texas Hlth San Antonio, Pharmacotherapy Educ & Res Ctr, Sch Med, 7703 Floyd Curl Dr,MC 6220, San Antonio, TX 78229 USA
来源
ONCOLOGIST | 2023年 / 28卷 / 09期
基金
美国国家卫生研究院;
关键词
lung cancer; durvalumab; health equity; health disparity; immunotherapy; RACIAL DISPARITIES; PROSTATE-CANCER; CLINICAL-TRIALS; UNITED-STATES; SURVIVAL; RACE; CARE; OUTCOMES; AFFAIRS; IMPACT;
D O I
10.1093/oncolo/oyad172
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Black patients shoulder a disproportionate share of the lung cancer burden in the US but are underrepresented in landmark immunotherapy trials. This analysis is the first study to evaluate the relationship between race and the clinical use of durvalumab. Background Real-world evidence is limited regarding the relationship between race and use of durvalumab, an immunotherapy approved for use in adults with unresectable stage III non-small cell lung cancer (NSCLC) post-chemoradiotherapy (CRT). This study aimed to evaluate if durvalumab treatment patterns differed by race in patients with unresectable stage III NSCLC in a Veterans Health Administration (VHA) population. Materials and Methods This was a retrospective analysis of White and Black adults with unresectable stage III NSCLC treated with durvalumab presenting to any VHA facility in the US from January 1, 2017, to June 30, 2020. Data captured included baseline characteristics and durvalumab treatment patterns, including treatment initiation delay (TID), interruption (TI), and discontinuation (TD); defined as CRT completion to durvalumab initiation greater than 42 days, greater than 28 days between durvalumab infusions, and more than 28 days from the last durvalumab dose with no new durvalumab restarts, respectively. The number of doses, duration of therapy, and adverse events were also collected. Results A total of 924 patients were included in this study (White = 726; Black = 198). Race was not a significant factor in a multivariate logistic regression model for TID (OR, 1.39; 95% CI, 0.81-2.37), TI (OR, 1.58; 95% CI, 0.90-2.76), or TD (OR, 0.84; 95% CI, 0.50-1.38). There were also no significant differences in median (interquartile range [IQR]) number of doses (White: 15 [7-24], Black: 18 [7-25]; P = .25) or median (IQR) duration of therapy (White: 8.7 months [2.9-11.8], Black: 9.8 months [3.6-12.0]; P = .08), although Black patients were less likely to experience an immune-related adverse event (28% vs. 36%, P = .03) and less likely to experience pneumonitis (7% vs. 14%, P < .01). Conclusion Race was not found to be linked with TID, TI, or TD in this real-world study of patients with unresectable stage III NSCLC treated with durvalumab at the VHA.
引用
收藏
页码:804 / 811
页数:8
相关论文
共 50 条
  • [31] A Glimpse Into the Future for Unresectable Stage III Non-Small Cell Lung Cancer
    Bartolomeo, Valentina
    Cortiula, Francesco
    Hendriks, Lizza E. L.
    De Ruysscher, Dirk
    Filippi, Andrea R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : 1455 - 1460
  • [32] Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer
    Vokes, EE
    Crawford, J
    Bogart, J
    Socinski, MA
    Clamon, G
    Green, MR
    CLINICAL CANCER RESEARCH, 2005, 11 (13) : 5045S - 5050S
  • [33] Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients
    Kazutaka Hosoya
    Daichi Fujimoto
    Hayato Kawachi
    Yuki Sato
    Mariko Kogo
    Kazuma Nagata
    Atsushi Nakagawa
    Ryo Tachikawa
    Shinya Hiraoka
    Masaki Kokubo
    Keisuke Tomii
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 275 - 280
  • [34] PACIFIC: An Ocean of Hope in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
    Uprety, Dipesh
    Marinier, David E.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (05): : 458 - 460
  • [35] Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients
    Hosoya, Kazutaka
    Fujimoto, Daichi
    Kawachi, Hayato
    Sato, Yuki
    Kogo, Mariko
    Nagata, Kazuma
    Nakagawa, Atsushi
    Tachikawa, Ryo
    Hiraoka, Shinya
    Kokubo, Masaki
    Tomii, Keisuke
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (02) : 275 - 280
  • [36] Durvalumab consolidation therapy following chemoradiotherapy among patients with unresectable stage III non-small cell lung cancer (NSCLC) treated in a US community oncology network
    Waterhouse, David Michael
    Yong, Candice
    Robert, Nicholas J.
    Aguilar, Kathleen M.
    Ndukum, Juliet
    Xie, Yiqiong
    Seal, Brian S.
    Cotarla, Ion
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
  • [37] Real world experience of survival outcomes in consolidative durvalumab in unresectable stage III non-small cell lung cancer (NSCLC)
    Pringle, Nicole
    Fletcher, James
    Arneil, Melissa
    Xu, Wen
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 47 - 48
  • [38] Real World Experience of Survival Outcomes in Consolidative Durvalumab in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
    Pringle, N.
    Fletcher, J. A.
    Morton, C.
    Mullally, W. J.
    Arneil, M.
    O'Byrne, K.
    Xu, W.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S569 - S569
  • [39] Blood-Based Biomarker Analysis for Predicting Efficacy of Chemoradiotherapy and Durvalumab in Patients with Unresectable Stage III Non-Small Cell Lung Cancer
    Park, Cheol-Kyu
    Lee, Sung-Woo
    Cho, Hyun-Ju
    Oh, Hyung-Joo
    Kim, Young-Chul
    Kim, Yong-Hyub
    Ahn, Sung-Ja
    Cho, Jae-Ho
    Oh, In-Jae
    CANCERS, 2023, 15 (04)
  • [40] Outcomes of patients with unresectable stage III non-small cell lung cancer treated with durvalumab and subsequent therapies after disease progression.
    Dickson, Franco Adjei-Baffour
    Raez, Luis E.
    Dumais, Katerine
    Powery, Herman W.
    Walker, Damaal
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)